Eton Pharmaceuticals to Present at 2026 Jefferies Global Healthcare Conference in London

Eton Pharmaceuticals (Nasdaq: ETON) will present at the 2026 Jefferies Global Healthcare Conference in London on November 16, 2026.

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

Eton Pharmaceuticals (Nasdaq: ETON) will present at the 2026 Jefferies Global Healthcare Conference in London on November 16, 2026. Members of its executive leadership team are scheduled to present from 3:00–3:25 PM GMT / 10:00–10:25 AM EST. A webcast will be available.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

11/04/2026 - 04:30 PM EST

DEER PARK, Ill., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company’s executive leadership team will present at the 2026 Jefferies Global Healthcare Conference in London from November 16-19, 2026 as follows:

Date: Monday, November 16th at 3:00-3:25 PM Greenwich Mean Time (GMT)/10:00-10:25 AM Eastern Standard Time (EST)

Webcast: https://event.summitcast.com/view/avibSrFufLKeoLRAEgMxy6/439Zc3DM73bAusVSPjtSFs

About Eton Pharmaceuticals

Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has twelve rare disease products: KHINDIVI^® (hydrocortisone), INCRELEX^® (mecasermin), ALKINDI SPRINKLE^® (hydrocortisone), DESMODA^™ (desmopressin acetate), GALZIN^® (zinc acetate), HEMANGEOL^® (propranolol hydrochloride), PKU GOLIKE^®, IMPAVIDO^® (miltefosine), LIBERVANT^® (diazepam), Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has six additional product candidates in late-stage development: AMGLIDIA^® (glyburide oral suspension), ASN-001, ET-700, ET-800, ET-900, and ZENEO^® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com.